Deals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has entered into an exclusive worldwide (excluding Korea) license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to co‑develop and…

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones
CancerHansoh Pharmaceutical

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform
AIFangzhou

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves' Disease Deal
Changchun High & New Technology IndustriesSaizeng Medical Technology

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials
CircurnauBriGene Biosciences

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Show More